A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Mise à jour : Il y a 4 ans
Référence : NCT01790100

Femme et Homme

Extrait

The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C infection.


Critère d'inclusion

  • Chronic hepatitis C

Liens